Prenetics Global Limited (NASDAQ: PRE) reported a mixed set of results for the second quarter of fiscal year 2026, with earnings per share beating analyst expectations while total revenue fell short of consensus estimates.

The company recorded a loss per share of $(0.53), which beat the analyst consensus estimate of $(0.71) by 25.35 percent. This represents a significant improvement over the loss of $(0.82) per share reported in the same period last year, marking a 35.37 percent reduction in losses year-on-year.

However, top-line growth did not meet market expectations. Prenetics reported quarterly sales of $46.488 million, missing the analyst consensus estimate of $48.920 million by 4.97 percent. Despite the miss against estimates, this figure represents a robust 162.94 percent increase over sales of $17.680 million in the same period last year.

Financial Performance and Guidance

The previous reporting highlighted a consolidated revenue of $46.5 million, driven primarily by the IM8 brand. The new data refines this figure to $46.488 million. The IM8 brand, co-founded with David Beckham, remains the primary growth engine, having generated $45.0 million in revenue for the quarter in prior disclosures, marking a 359% year-on-year surge.

Management had previously highlighted July 2026 as the strongest month in the company’s history, with IM8 recording $20.9 million in monthly revenue. Building on this momentum, Prenetics raised its full-year FY26 guidance for IM8 revenue to $220-230 million and initiated guidance for fiscal year 2027, projecting IM8 revenue of $400 million or more.

What the Numbers Show

The divergence between earnings performance and revenue expectations highlights the operational leverage achieved by the company. While revenue missed the specific consensus target of $48.920 million, the actual figure of $46.488 million still represents a massive 162.94% expansion from the prior year’s $17.680 million. More notably, the improvement in EPS from $(0.82) to $(0.53) suggests that cost structures are scaling more efficiently than revenue, allowing the company to reduce its loss burden significantly even as it navigates slight shortfalls against high market expectations.

Cash Flow and Strategic Shifts

A key operational milestone was achieved in July 2026, when the company recorded its first month of positive consolidated Adjusted Free Cash Flow. Management expects this metric to remain positive for the third quarter and beyond. The financial results reflect a strategic repositioning under IFRS 5, with discontinued operations presented separately following the divestiture of non-core businesses such as ACT Genomics, Europa, and Insighta.

Prenetics Global Limited (NASDAQ: PRE) will report its financial results for the second quarter of 2026, ended June 30, 2026, before market open on Tuesday, August 18, 2026. The announcement confirms the timing for investors seeking updates on the consumer health company’s performance and strategy. Prenetics, parent of the AI-native direct-to-consumer wellness brand IM8 co-founded by David Beckham, is also altering its standard disclosure format to provide shareholders with a more comprehensive view of its operations.

Beginning with this quarter, the company will replace its traditional earnings press release with a detailed shareholder letter and an accompanying investor deck. These documents will be published on its investor relations website at https://ir.prenetics.com/ . This shift aims to offer deeper insights into the company’s performance, strategic direction, and outlook compared to standard regulatory filings.

On the same day, August 18, 2026, management will host a live-streamed earnings event on Stocktwits starting at 8:30 a.m. Eastern Time. During this session, executives will discuss the quarterly results and hold a question-and-answer period. Investors can access the live stream at https://stocktwits.com/symbol/PRE . Those wishing to submit questions in advance may email investors@prenetics.com . A replay of the event will be available on the company’s investor relations website following the broadcast.

Upcoming Investor Conferences

Prenetics management has scheduled participation in several upcoming investor conferences to engage with analysts and shareholders. The schedule includes appearances at major growth and sector-specific events across Boston and New York City.

The fireside chat at the Canaccord Genuity conference will be available for viewing via a dedicated link and on the company’s investor relations website. Investors interested in scheduling one-on-one meetings with management can contact Investor Relations at PRE@mzgroup.us or reach out through their conference representatives.

Company Background

Prenetics Global Limited operates as a leading consumer health company focused on advancing human health and longevity. Its flagship brand, IM8, is positioned as a premium daily nutrition system anchored by Daily Ultimate Essentials, a 90-ingredient formula that is NSF Certified for Sport and clinically studied. IM8 has surpassed $200 million in annualized run-rate revenue within 18 months of launch, shipping to 46 countries and delivering approximately 200,000 servings daily. The brand’s ambassador and equity-partner roster includes David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman, Jay Shetty, and Inter Miami CF.